Cerus multi-layered sales growth trajectory 'convincing,' says Cowen » 14:0708/1008/10/20
Cowen analyst Joshua…
Cowen analyst Joshua Jennings says that Cerus multi-year multi-layered sales growth trajectory is "convincing." The American Red Cross' commitment to transition to 100% INTERCEPT Platelets alone could drive 15%-20%-plus top line growth in 2021/2022, he contends. Further, the analyst notes that numerous growth opportunities are also "evolving nicely" including the non-ARC U.S. platelet opportunity, the German platelet market, INTERCEPT Cryo, and INTERCEPT RBCs. Jennings reiterates an Outperform rating on the shares, with a $9.50 price target on the stock.
Aspen Group reports 2,351 new student enrollments in Q1 » 09:1608/1008/10/20
Aspen Group announced a…
Survey indicates strengthening recovery in Apple iPhone sales, says KeyBanc » 07:0208/1008/10/20
AAPL, AVGO, QCOM, SWKS, SYNA
KeyBanc analyst John Vinh…
Aclaris continues to pursue strategic alternatives, including seeking partners » 07:2408/0708/07/20
Aclaris continues to…
Aclaris continues to pursue strategic alternatives, including seeking partners for: A-101 45% Topical Solution: to obtain regulatory approval and commercialize A-101 45% Topical Solution, an investigational compound, as a potential treatment for common warts; ATI-501 & ATI-502: to further develop, obtain regulatory approval and commercialize ATI-501 and ATI-502, investigational JAK 1/3 inhibitor compounds, as potential treatments for alopecia; and ESKATA: to commercialize ESKATA topical solution, 40%.
Aclaris Therapeutics to submit IND for ATI-2138 in 2021 » 07:2308/0708/07/20
Aclaris is developing…
Aclaris is developing ATI-2138 as a potential treatment for psoriasis and/or inflammatory bowel disease and expects to submit an IND for ATI-2138 in 2021.
Aclaris Therapeutics to initiate Phase 1/2a trial of ATI-1777 in 2H20 » 07:2208/0708/07/20
ATI-1777-AD-201: Aclaris expects to initiate a Phase 1/2a multicenter, randomized, double-blind, vehicle-controlled trial to investigate the safety, tolerability, pharmacokinetics and efficacy of topically applied ATI-1777 in subjects with moderate to severe AD in the second half of 2020. The primary endpoint will assess efficacy at four weeks.
Aclaris Therapeutics to progress to first-in-human trial of ATI-1777 » 07:2208/0708/07/20
Aclaris submitted an…
Aclaris submitted an Investigational New Drug Application for ATI-1777 for the treatment of moderate to severe atopic dermatitis in June 2020 and now plans to progress to the first-in-human trial of ATI-1777 in subjects with moderate to severe AD.
Aclaris Therapeutics expects to initiate ATI-450-CAPS-201 trial in 2H20 » 07:2108/0708/07/20
ATI-450-CAPS-201: Aclaris expects to initiate a Phase 2a clinical trial of ATI-450 in cryopyrin-associated periodic syndrome, an IL1beta-driven disease, in the second half of 2020.
Aclaris Therapeutics sees data from ATI-450-RA-201 trial in 1H21 » 07:2008/0708/07/20
ATI-450-RA-201: An ongoing Phase 2a trial to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of ATI-450 in subjects with moderate to severe rheumatoid arthritis. This trial was initiated in March 2020. Due to the COVID-19 pandemic, Aclaris temporarily paused enrollment. Aclaris resumed enrolling subjects, and the first subject was dosed, in May 2020. At this time, Aclaris is actively recruiting for this trial. Given the continuing evolution of the COVID-19 pandemic, Aclaris now anticipates reporting data from this trial in the first half of 2021.
Aclaris Therapeutics expects cash to be sufficient through 1Q22 » 07:0508/0708/07/20
Aclaris anticipates that…
Aclaris anticipates that its cash, cash equivalents and marketable securities as of June 30, 2020 will be sufficient to fund its operations through the first quarter of 2022, without giving effect to any potential business development transactions or financing activities.